MedTrace Logo

Safety and Immunogenicity Study of GX-70 in TB Patient

NCT03159975 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-01-11

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability, and immunogenicity in patients with pulmonary tuberculosis of an investigational DNA vaccine being developed for the prevention of relapse of tuberculosis.

Conditions

  • Pulmonary Tuberculoses
  • High Risk Factors for Relapse
  • Treatment Failure

Interventions

DRUG

GX-70 by electroporation

Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times

DRUG

GX-70 by electroporation

Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times

DRUG

GX-70 by electroporation

Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-31
Primary Completion
2018-08-31
Completion
2018-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03159975 on ClinicalTrials.gov